Cancer treatment firm Sirtex Medical is directing attention to a study being presented on Thursday at the American Society of Clinical Oncology (ASCO) annual meeting.
The results are from the first large multicenter study to evaluate selective internal radiation therapy (SIRT) with the company's SIR-Spheres microspheres in patients 70 and older, according to Sirtex. The findings suggest that use of the microspheres in elderly patients with unresectable colorectal liver metastases is as effective and well-tolerated as in younger patients, the company said.
Due to the minimally invasive nature of microsphere therapy, lead investigator Dr. Andrew Kennedy, from Sarah Cannon Research Institute in Nashville, TN, and researchers hypothesized that SIRT may provide an effective treatment option for older patients without the concern of side effects often seen with chemotherapy, Sirtex said.
